Proxima Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Proxima Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-25,000	Closed	-$681K	–	31
2019 Q3	$681K	Sell	25,000 -10,000	-29%	-$259K	1.05%	20
2019 Q2	$842K	Hold	35,000	–	–	1.13%	22
2019 Q1	$925K	Sell	35,000 -20,000	-36%	-$474K	1.02%	23
2018 Q4	$1.07M	Buy	+55,000	New	+$1.08M	1.02%	24
2018 Q2	–	Sell	-257,000	Closed	-$3.65M	–	41
2018 Q1	$3.65M	Sell	257,000 -3,000	-1%	-$44.3K	2%	20
2017 Q4	$3.8M	Sell	260,000 -6,311	-2%	-$88.6K	2.2%	19
2017 Q3	$3.38M	Hold	266,311	–	–	1.89%	23
2017 Q2	$3.16M	Buy	266,311 +20,000	+8%	+$249K	1.71%	22
2017 Q1	$3.64M	Buy	246,311 +26,311	+12%	+$426K	2.22%	20
2016 Q4	$3.56M	Buy	+220,000	New	+$3.99M	1.79%	20

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Proxima Capital Management's HZNP Position: Q4 2019 in Review

Proxima Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2019, closing a stake of 25,000 shares — an estimated $681K sold.

Proxima Capital Management first reported a position in HZNP in Q4 2016 and held it in 10 quarters. The position peaked at $3.8M in Q4 2017. 281 funds tracked by Wall St. Rank hold HZNP as of Q4 2019.

Proxima Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2019 after selling out during the quarter.
Proxima Capital Management sold 25,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2019, an estimated $681K.
Proxima Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2016 and held it in 10 quarters.
Proxima Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.8M in Q4 2017.
281 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2019.

Based on Proxima Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.